Hanyang Bio-Tech to be listed on Emerging Stock Board on 5/20, focusing on ADC drug field
NQ Score
0/100
N1 Content Completeness
0
AI Summary (NQ-processed)
Hanyang Bio-Tech will be listed on the Emerging Stock Board on May 20, focusing on ADC (Antibody-Drug Conjugate) new drug technology platform development. General Manager Lin Yang-Sheng stated that substantial negotiations are underway with several domestic and international biotech and pharmaceutical companies for technology platform applications, and specific licensing results are hoped for in the near future.